Subcutaneous route non-inferior to intravenous for efgartgimod in myasthenia gravis

In the Adapt-SC trial, 110 adults with generalised myasthenia gravis received a weekly subcutaneous (SC) or intravenous (IV) injection of efgartgimod (Vyvgart®) for 4 weeks. The results show :

• non-inferiority of the SC route over the IV route in terms of the percentage reduction in blood IgG levels (primary endpoint of the trial) ;
• a significant clinical improvement and good safety profile for both routes of administration.

The same publication reports interim results from the Adapt-SC+ open-label extension, which confirms similar trends. The trial is due to end in December 2024.

 

Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+). Howard JF Jr, Vu T, Li G et al. Neurotherapeutics. 2024 Sep 2:e00378.